How Long Is a Titer Test Good For? A Validity Breakdown

A titer test measures circulating antibodies in your blood at the moment the sample is drawn, so the result itself is a snapshot that never “expires” in a technical sense. What changes is whether that antibody level still means you are protected. For some diseases, a single positive titer can be trusted for decades; for others, protection wanes within months. The answer depends on which pathogen the test targets, how you acquired immunity, and several personal factors including your age and immune status.

What a Titer Result Actually Tells You

A titer test detects and quantifies antibodies your immune system has produced against a specific pathogen or vaccine antigen. When a lab reports a number above a defined cutoff, the standard interpretation is that you have “protective” levels. But circulating antibodies are only one layer of immune defense. Your body also maintains memory B cells and long-lived plasma cells that can ramp up antibody production if you encounter the pathogen again, even years after the measurable antibodies in your blood have dropped below the threshold. A study of elderly adults who received a hepatitis B booster nine years after vaccination found robust recall responses regardless of where their pre-booster titers stood, confirming that immune memory persists well beyond what a single blood draw reveals.¹

This distinction matters because a titer that has fallen below the “protective” line does not necessarily mean you are unprotected. It means the first-responder antibodies floating in your bloodstream have thinned out. Whether your deeper immune memory can still mobilize quickly enough to prevent disease is a separate question, and one that a standard titer test cannot answer directly.

The Two-Phase Pattern of Antibody Decay

Antibodies do not disappear at a steady rate. Research consistently shows a two-phase pattern: a steep initial drop in the weeks and months after vaccination or infection, followed by a much slower decline that can plateau for years. For SARS-CoV-2, neutralizing antibody levels drop with a half-life of roughly 30 to 60 days during that first steep phase before leveling off.² A large longitudinal study tracked vaccinated individuals for over 400 days and found an initial five-fold drop in antibody titers followed by stabilization, where titers barely budged month to month.³

This means the timing of your titer test relative to your last vaccination or infection heavily influences the number. A test drawn three weeks after a booster will catch you near a peak. A test drawn six months later will catch you in the trough of that first fast decline. And a test drawn two years later may show a level that looks worryingly low but is actually sitting on a stable plateau that could persist for much longer. Understanding this curve is essential for interpreting what your result means over time.

Measles, Mumps, and Rubella

MMR titers are among the longest-lasting in medicine. After two doses of measles vaccine, antibodies persisted in all children followed for ten years in one study, with no completely seronegative results detected at the end of the observation period.⁴ A positive measles titer is generally accepted as evidence of lifelong immunity, and most employers and schools treat a documented positive result as permanent.

That said, vaccine-induced measles antibodies do fade faster than antibodies from natural infection. An Italian retrospective study found the rate of losing detectable IgG was about four and a half times higher in people who were vaccinated compared to those who had measles as children.⁵ Even so, the absolute rate of becoming seronegative remained low. For practical purposes, if your measles titer comes back positive, you are very unlikely to need retesting unless you are immunocompromised or face an unusual exposure situation.

Hepatitis B

Hepatitis B titer validity is a common concern for healthcare workers, who often need proof of immunity for employment. The standard protective threshold is 10 mIU/mL of anti-HBs antibody. A study of a mixed cohort of healthcare workers found that the large majority maintained titers above 100 mIU/mL after vaccination, but there was a clear decline as years passed since the last dose, and older workers were more likely to fall below protective levels.⁶

Here is where the distinction between circulating antibodies and immune memory becomes especially relevant. Even when anti-HBs titers drop below 10 mIU/mL years after vaccination, most people still mount a strong recall response when given a booster, indicating their immune memory is intact. Research on elderly individuals who received a booster nine years after their initial hepatitis B series showed robust antibody surges, and the strength of that recall response correlated with whatever residual titers they had before the booster.¹ Current CDC guidance reflects this: a documented history of a complete hepatitis B series plus at least one post-vaccination titer above 10 mIU/mL is generally accepted as evidence of lasting immunity, without requiring periodic retesting for most people.

Tetanus and Diphtheria

Tetanus is the classic case where booster schedules and titer longevity diverge. The standard recommendation in most countries is a booster every ten years. But the actual antibody data suggest that protection lasts considerably longer than that. A serosurvey of university students and at-risk workers found that ten years after the last dose, 95% still had antibodies above the protective level, and about half of those had levels considered “long-term protective.” When subjects had received five lifetime doses, the data suggested a booster was unnecessary for up to 20 years.⁷

A study of military personnel reinforced this, estimating that a single booster dose produced protective antibody levels lasting up to 22 years, and that receiving two or more boosters made a meaningful difference in antibody persistence within the first decade.⁸ Researchers in both studies suggested that checking a titer before giving a booster would be reasonable, partly to avoid unnecessary injections and partly because over-immunization with tetanus toxoid can cause uncomfortable local reactions. In practice, though, most clinics still follow the ten-year schedule because it is simpler than drawing blood for every patient.

COVID-19 and Influenza

Respiratory virus titers are the shortest-lived of the common vaccines, and this is where the “how long is my titer good for” question becomes most frustrating. For SARS-CoV-2, vaccine-only immunity produced antibodies with a half-life of roughly 117 days in one study, meaning antibody levels dropped by half every four months or so. Titers stayed above an estimated 50% protection threshold for fewer than five months.⁹ People with hybrid immunity, meaning they had both vaccination and at least one prior infection, fared considerably better. Their antibody half-life roughly doubled to about 242 days, and they stayed above the same 50% protection threshold for nearly a year.⁹

When looking at the longer-lived IgG response rather than neutralizing antibodies specifically, a modeling study estimated that people with hybrid immunity had a median IgG half-life of about 810 days for spike-protein antibodies, compared to roughly 451 days for those who received mRNA vaccines without prior infection.¹⁰ The gap between neutralizing antibodies (which block the virus directly) and total IgG (which may or may not neutralize) matters. A titer test measuring binding antibodies can come back positive long after your neutralizing capacity has dropped. And with a virus that mutates rapidly, even high titers against an older variant may not protect well against the latest one. A Canadian cohort study found that neutralizing antibodies from wild-type infection alone were largely ineffective against newer variants, while hybrid immunity produced a much broader neutralization profile.¹¹

Influenza presents a similar challenge. Antibody titers from flu vaccination wane substantially between seasons, with studies in older adults showing declines ranging from about 18% to over 60% depending on the vaccine strain and how titers were measured.¹² Combined with the virus’s annual antigenic drift, this is why flu vaccination is recommended every year and why a flu titer from last season tells you very little about your protection going into the next one.

Rabies

Rabies titer testing has a unique regulatory dimension. The World Health Organization defines a protective titer as 0.5 IU/mL or above, and many countries require proof of this level for pet import or for workers at risk of animal bites. A retrospective study from India found that about 93% of vaccinated individuals maintained protective titers, with an average titer of 3.81 IU/mL. The analysis identified five years as the point where booster doses become advisable.¹³ For travelers and veterinary professionals, this means a titer drawn within the past two to three years is generally accepted, but requirements vary by country and employer. Some border authorities demand a test within a specific window regardless of how high the previous result was.

Why Your Titer May Fade Faster or Slower Than Average

The timelines above are population averages, and individual variation is enormous. Several factors reliably push your antibody trajectory in one direction or another.

Age is the most studied factor. Older adults tend to produce fewer antibodies after vaccination, though the antibodies they do produce work just as well. A study of tick-borne encephalitis vaccine found that elderly recipients had lower antibody quantities but no reduction in antibody quality or functional activity compared to younger adults.¹⁴ For influenza specifically, aging is associated with reduced antibody responses to both infection and vaccination, though individuals who enter the season with higher baseline titers from prior exposures tend to fare better.¹⁵

Sex plays a role too. Females generally develop higher antibody responses to vaccines than males, a pattern attributed to hormonal, genetic, and microbiome differences. The flip side is that females also tend to experience more side effects after vaccination.

Immunosuppression can dramatically shorten how long titers remain detectable. Stem cell transplant recipients showed significant antibody declines at three and six months after COVID-19 vaccination, though those who had been infected before vaccination maintained more stable levels.¹⁶ In children undergoing chemotherapy, the number of treatment sessions was a powerful predictor of losing protection. Children who received 30 or more chemotherapy sessions had dramatically higher odds of becoming seronegative to multiple vaccines they had previously been immunized against.¹⁷ If you are on immunosuppressive medications or have undergone treatments that reset your immune system, a titer from before your treatment may be meaningless. Repeat testing after immune reconstitution is standard practice.

Lab Methods Can Move the Numbers Substantially

Not all titer tests are measuring the same thing, even when they claim to measure antibodies against the same pathogen. A comparison of ten different commercial serological tests for SARS-CoV-2 antibodies found that correlation with actual virus-neutralizing ability ranged from moderate to strong, with sensitivity anywhere from 35% to 100% and specificity from 35% to 90%.¹⁸ A CDC analysis underscored the problem further: even when labs used the WHO international standard to calibrate their SARS-CoV-2 neutralization assays, the reported values still varied by up to 50-fold depending on which assay was used.¹⁹

The practical takeaway here is that comparing a titer value from one lab to a value from a different lab, or to a threshold that was established using a different assay, can be misleading. If you are tracking your antibody levels over time, getting your tests done at the same laboratory using the same method will give you the most meaningful trend. For well-established vaccines like MMR and hepatitis B, commercial assays have been standardized for years and this is less of a concern. For newer pathogens, assay variability remains a real source of confusion.

False Positives and Cross-Reactivity

Titer tests can occasionally report antibodies that are not actually there, or detect antibodies that are reacting to the wrong target. False positive results occur when other immunoglobulins in the blood bind nonspecifically to the test components. These cross-reacting antibodies may come from exposure to a different pathogen, from rheumatoid factor, or from generalized immune activation that produces a wide scatter of antibodies.²⁰ For most vaccine titers this is rare, but it becomes relevant for pathogens that are closely related to common viruses. If a titer result does not make clinical sense given your history, a confirmatory test using a different method is the usual next step.

Titer Testing for Dogs and Cats

The question of titer validity comes up frequently in veterinary medicine, where pet owners increasingly ask whether titer testing can replace annual revaccination. For dogs, the evidence supports the idea that core vaccine antibodies last much longer than a year. A multi-hospital study found that the majority of dogs had measurable vaccine titers to distemper, adenovirus, and parvovirus regardless of how long ago they were vaccinated. Titers to adenovirus and parvovirus did decline with time since vaccination, but most dogs still had levels within acceptable ranges years later.²¹

In-clinic point-of-care titer kits have made testing more accessible but introduce their own complications. A comparison of three commercial rapid tests against the gold standard of virus neutralization found that agreement ranged from 62% to 82%, with one popular test recommending vaccination for nearly every dog tested, including many that clearly had protective levels on the reference assay.²² If your vet uses a rapid kit and it says your dog needs revaccination, asking which test was used and whether a send-out lab test might give a more accurate picture is reasonable. Many veterinary immunologists recommend titer testing every three years for core canine vaccines, reserving boosters for dogs whose titers actually fall below the protective cutoff.

When Titer Thresholds Themselves Are Uncertain

For certain diseases, the challenge is not just how fast antibodies decay but whether anyone has agreed on what level actually protects you. SARS-CoV-2 is the starkest example. One study identified a specific IgG threshold above which close contacts of infected individuals had a 68% lower risk of catching the virus and an 85% lower risk of moderate or severe disease at a lower threshold.²³ But those thresholds were derived from one population using one assay, and research on variant-specific antibodies shows that even the type of antibody measured changes the picture. Neutralizing antibodies specific to the circulating variant mediated a much larger share of protection than antibodies measured against the original virus strain.²⁴

For well-studied vaccines like hepatitis B and tetanus, agreed-upon thresholds have been validated across decades and millions of people. For newer or rapidly evolving pathogens, a titer number alone can be hard to interpret without knowing which assay was used, which variant is circulating, and what the latest correlates-of-protection data show. In those situations, clinical context and vaccination history often matter more than the number on the lab report.